IL-1ra Delivered from Poly(lactic-co-glycolic Acid) Microspheres Attenuates IL-1β-mediated Degradation of Nucleus Pulposus in Vitro

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2012 Aug 7

PMID 22863285

Citations 42

Authors

Deborah J Gorth

Robert L Mauck

Joseph A Chiaro

Bhavana Mohanraj

Nader M Hebela

George R Dodge

Dawn M Elliott

Lachlan J Smith

Affiliations

Soon will be listed here.

Abstract

Introduction: Inflammation plays a key role in the progression of intervertebral disc degeneration, a condition strongly implicated as a cause of lower back pain. The objective of this study was to investigate the therapeutic potential of poly(lactic-co-glycolic acid) (PLGA) microspheres loaded with interleukin-1 receptor antagonist (IL-1ra) for sustained attenuation of interleukin-1 beta (IL-1β) mediated degradative changes in the nucleus pulposus (NP), using an in vitro model.

Methods: IL-1ra was encapsulated in PLGA microspheres and release kinetics were determined over 35 days. NP agarose constructs were cultured to functional maturity and treated with combinations of IL-1β and media conditioned with IL-1ra released from microspheres at intervals for up to 20 days. Construct mechanical properties, glycosaminoglycan content, nitrite production and mRNA expression of catabolic mediators were compared to properties for untreated constructs using unpaired Student's t-tests.

Results: IL-1ra release kinetics were characterized by an initial burst release reducing to a linear release over the first 10 days. IL-1ra released from microspheres attenuated the degradative effects of IL-1β as defined by mechanical properties, glycosaminoglycans (GAG) content, nitric oxide production and mRNA expression of inflammatory mediators for 7 days, and continued to limit functional degradation for up to 20 days.

Conclusions: In this study, we successfully demonstrated that IL-1ra microspheres can attenuate the degradative effects of IL-1β on the NP for extended periods. This therapeutic strategy may be appropriate for treating early-stage, cytokine-mediated disc degeneration. Ongoing studies are focusing on testing IL-1ra microspheres in an in vivo model of disc degeneration, as a prelude to clinical translation.

Citing Articles

PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration.

Snuggs J, Senter R, Whitt J, Jackson J, Le Maitre C Gene Ther. 2024; .

PMID: 39572769 DOI: 10.1038/s41434-024-00504-7.

IL-1 receptor antagonist: etiological and drug delivery systems overview.

Ubhe A Inflamm Res. 2024; 73(12):2231-2247.

PMID: 39455436 DOI: 10.1007/s00011-024-01960-y.

Progress in regulating inflammatory biomaterials for intervertebral disc regeneration.

Xiang H, Zhao W, Jiang K, He J, Chen L, Cui W Bioact Mater. 2024; 33:506-531.

PMID: 38162512 PMC: 10755503. DOI: 10.1016/j.bioactmat.2023.11.021.

Updates on Pathophysiology of Discogenic Back Pain.

Jha R, Bernstock J, Chalif J, Hoffman S, Gupta S, Guo H J Clin Med. 2023; 12(21).

PMID: 37959372 PMC: 10647359. DOI: 10.3390/jcm12216907.

IL-1β-mediated inflammatory responses in intervertebral disc degeneration: Mechanisms, signaling pathways, and therapeutic potential.

Li H, Pan H, Xiao C, Li H, Long L, Wang X Heliyon. 2023; 9(9):e19951.

PMID: 37809657 PMC: 10559578. DOI: 10.1016/j.heliyon.2023.e19951.

References

Mauck R, Seyhan S, Ateshian G, Hung C . Influence of seeding density and dynamic deformational loading on the developing structure/function relationships of chondrocyte-seeded agarose hydrogels. Ann Biomed Eng. 2002; 30(8):1046-56. DOI: 10.1114/1.1512676. View

Zanette D, Dundon W, Soffientini A, Sottani C, Marinelli F, AKESON A . Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification. J Biotechnol. 1998; 64(2-3):187-96. DOI: 10.1016/s0168-1656(98)00111-4. View

Farndale R, Sayers C, Barrett A . A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res. 1982; 9(4):247-8. DOI: 10.3109/03008208209160269. View

Le Maitre C, Pockert A, Buttle D, Freemont A, Hoyland J . Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans. 2007; 35(Pt 4):652-5. DOI: 10.1042/BST0350652. View

Fleischmann R, Stern R, Iqbal I . Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004; 4(8):1333-44. DOI: 10.1517/14712598.4.8.1333. View

Le Maitre C, Freemont A, Hoyland J . Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol. 2004; 204(1):47-54. DOI: 10.1002/path.1608. View

Pisal D, Kosloski M, Balu-Iyer S . Delivery of therapeutic proteins. J Pharm Sci. 2010; 99(6):2557-75. PMC: 2857543. DOI: 10.1002/jps.22054. View

Braddock M, Quinn A . Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004; 3(4):330-9. DOI: 10.1038/nrd1342. View

Urban J, Smith S, Fairbank J . Nutrition of the intervertebral disc. Spine (Phila Pa 1976). 2004; 29(23):2700-9. DOI: 10.1097/01.brs.0000146499.97948.52. View

10.

Goupille P, Mulleman D, Chevalier X . Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther. 2007; 9(6):110. PMC: 2246235. DOI: 10.1186/ar2324. View

11.

Takeda K, Akira S . TLR signaling pathways. Semin Immunol. 2004; 16(1):3-9. DOI: 10.1016/j.smim.2003.10.003. View

12.

Nimni M . Collagen: structure, function, and metabolism in normal and fibrotic tissues. Semin Arthritis Rheum. 1983; 13(1):1-86. DOI: 10.1016/0049-0172(83)90024-0. View

13.

Hoyland J, Le Maitre C, Freemont A . Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology (Oxford). 2008; 47(6):809-14. DOI: 10.1093/rheumatology/ken056. View

14.

Mirza S, Deyo R . Systematic review of randomized trials comparing lumbar fusion surgery to nonoperative care for treatment of chronic back pain. Spine (Phila Pa 1976). 2007; 32(7):816-23. DOI: 10.1097/01.brs.0000259225.37454.38. View

15.

Johnstone B, Hering T, Caplan A, Goldberg V, Yoo J . In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res. 1998; 238(1):265-72. DOI: 10.1006/excr.1997.3858. View

16.

Pockert A, Richardson S, Le Maitre C, Lyon M, Deakin J, Buttle D . Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum. 2009; 60(2):482-91. DOI: 10.1002/art.24291. View

17.

Yang Y, Chia H, Chung T . Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J Control Release. 2000; 69(1):81-96. DOI: 10.1016/s0168-3659(00)00291-1. View

18.

Moioli E, Hong L, Guardado J, Clark P, Mao J . Sustained release of TGFbeta3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells. Tissue Eng. 2006; 12(3):537-46. PMC: 4035024. DOI: 10.1089/ten.2006.12.537. View

19.

van de Weert M, Hennink W, Jiskoot W . Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2001; 17(10):1159-67. DOI: 10.1023/a:1026498209874. View

20.

Kitano T, Zerwekh J, Usui Y, EDWARDS M, Flicker P, Mooney V . Biochemical changes associated with the symptomatic human intervertebral disk. Clin Orthop Relat Res. 1993; (293):372-7. View